This is a routine IP portfolio expansion with no near-term revenue or clinical catalyst. Monitor for actual clinical trial results or regulatory decisions on existing programs (AUD, addiction, weight management) for meaningful price movement. The stock's historical pattern shows sustained negative drift on neutral filings — no reason to expect a reversal here.
Price Chart
Executive Summary
Clearmind Medicine filed a patent application in Hong Kong for novel psychedelic compounds targeting PTSD, expanding its global IP portfolio. The filing is a routine IP expansion with no new clinical data, financial results, or regulatory milestones — it does not change the company's near-term commercial or financial outlook. The $2M market cap micro-cap remains in a pre-revenue clinical stage with no material catalysts in this filing.
Key Facts
- Filed a patent application with the Hong Kong Patent Office for novel psychedelic compounds targeting PTSD and other mental health disorders
- Patent application is part of an exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem
- Global PTSD treatment market valued at approximately USD 18.5 billion in 2025, projected to reach USD 30.2 billion by 2035
- Company's IP portfolio consists of 19 patent families including 32 granted patents
- No new clinical data, financial results, or regulatory milestones were announced
Financial Impact
No financial impact — patent filing is a routine IP maintenance activity with no revenue or cost figures disclosed
Risk Factors
- Patent applications may not result in granted patents or may issue in a form not advantageous to the company
- Company is pre-revenue clinical-stage with no approved products and no disclosed cash runway
- Micro-cap biotech with $2M market cap carries extreme liquidity and dilution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079596 |
| Document: ea029853102ex99-1.htm | 0001213900-26-079596 |
| Document: 0001213900-26-079596-index-headers.html | 0001213900-26-079596 |
| Document: 0001213900-26-079596-index.html | 0001213900-26-079596 |
| Document: 0001213900-26-079596.txt | 0001213900-26-079596 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.80%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.06%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.97 (+532.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers